211 related articles for article (PubMed ID: 34367734)
21. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Generation of Stem Cell Memory-Like T Cells from Activated T Cells.
Ando M; Ikeda M; Yoshimura A; Kondo T
Methods Mol Biol; 2020; 2111():127-139. PubMed ID: 31933204
[TBL] [Abstract][Full Text] [Related]
23. Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges.
Kang S; Li Y; Qiao J; Meng X; He Z; Gao X; Yu L
Front Oncol; 2022; 12():787108. PubMed ID: 35356211
[TBL] [Abstract][Full Text] [Related]
24. Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities.
Van Caeneghem Y; De Munter S; Tieppo P; Goetgeluk G; Weening K; Verstichel G; Bonte S; Taghon T; Leclercq G; Kerre T; Debets R; Vermijlen D; Abken H; Vandekerckhove B
Oncoimmunology; 2017; 6(3):e1283460. PubMed ID: 28405508
[TBL] [Abstract][Full Text] [Related]
25. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML.
John S; Chen H; Deng M; Gui X; Wu G; Chen W; Li Z; Zhang N; An Z; Zhang CC
Mol Ther; 2018 Oct; 26(10):2487-2495. PubMed ID: 30131301
[TBL] [Abstract][Full Text] [Related]
26. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
28. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
29. Antigen-specific CD8+ memory stem T cells generated from human peripheral blood effectively eradicate allogeneic targets in mice.
Guan L; Li X; Wei J; Liang Z; Yang J; Weng X; Wu X
Stem Cell Res Ther; 2018 Dec; 9(1):337. PubMed ID: 30526661
[TBL] [Abstract][Full Text] [Related]
30. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Zhao Y; Parkhurst MR; Zheng Z; Cohen CJ; Riley JP; Gattinoni L; Restifo NP; Rosenberg SA; Morgan RA
Cancer Res; 2007 Mar; 67(6):2425-9. PubMed ID: 17363559
[TBL] [Abstract][Full Text] [Related]
31. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
32. Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.
Ataca Atilla P; McKenna MK; Tashiro H; Srinivasan M; Mo F; Watanabe N; Simons BW; McLean Stevens A; Redell MS; Heslop HE; Mamonkin M; Brenner MK; Atilla E
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32938629
[TBL] [Abstract][Full Text] [Related]
33. CAR'TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment.
Teppert K; Yonezawa Ogusuku IE; Brandes C; Herbel V; Winter N; Werchau N; Khorkova S; Wöhle C; Jelveh N; Bisdorf K; Engels B; Schaser T; Anders K; Künkele A; Lock D
Mol Ther Oncol; 2024 Jun; 32(2):200797. PubMed ID: 38601972
[TBL] [Abstract][Full Text] [Related]
34. Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.
Wang SY; Moore TV; Dalheim AV; Scurti GM; Nishimura MI
Sci Rep; 2021 Jun; 11(1):13327. PubMed ID: 34172810
[TBL] [Abstract][Full Text] [Related]
35. Rejuvenating Effector/Exhausted CAR T Cells to Stem Cell Memory-Like CAR T Cells By Resting Them in the Presence of CXCL12 and the NOTCH Ligand.
Ando M; Kondo T; Tomisato W; Ito M; Shichino S; Srirat T; Mise-Omata S; Nakagawara K; Yoshimura A
Cancer Res Commun; 2021 Oct; 1(1):41-55. PubMed ID: 36860911
[TBL] [Abstract][Full Text] [Related]
36. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
37. T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.
Lamers CH; van Steenbergen-Langeveld S; van Brakel M; Groot-van Ruijven CM; van Elzakker PM; van Krimpen B; Sleijfer S; Debets R
Hum Gene Ther Methods; 2014 Dec; 25(6):345-57. PubMed ID: 25423330
[TBL] [Abstract][Full Text] [Related]
38. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
39. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
